Krazati

Adagrasib, the active ingredient in Krazati, is a KRAS G12C inhibitor presented as a tablet for oral use. It treats KRAS G12C‑mutated non‑small cell lung cancer and KRAS G12C‑mutated colorectal cancer in adult patients.

GNH USA supplies Krazati as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Krazati targets KRAS G12C‑mutated cancers, a molecular subset of solid tumors.

- KRAS G12C‑mutated non‑small cell lung cancer: provides targeted inhibition of tumor growth in adult patients. - KRAS G12C‑mutated colorectal cancer: offers a molecularly targeted option for patients with this specific mutation.

Adagrasib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools. - Fatigue: reduced energy levels. - Decreased appetite: reduced food intake. - Vomiting: occasional episodes of emesis. - Elevated liver enzymes: mild transaminase increases.

Serious or Rare Side Effects: - Interstitial lung disease: inflammation of lung tissue requiring monitoring. - Cardiac toxicity: arrhythmias or reduced ejection fraction. - Severe hepatotoxicity: marked liver enzyme elevation or bilirubin rise. - Hematologic abnormalities: anemia or neutropenia. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing Adagrasib, clinicians should consider several safety precautions. - Baseline assessment: obtain liver function tests before initiating therapy. - Monitoring: perform regular CBC and liver enzyme panels during treatment. - Drug interactions: review concomitant medications for CYP3A4 substrates. - Pregnancy: avoid use unless potential benefit justifies risk; discuss with patient. - Breastfeeding: discontinue if nursing due to unknown excretion in milk. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture and light.

Adagrasib can affect and be affected by other medicines; interaction potential varies.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce adagrasib exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase exposure and toxicity. - Antacids containing aluminum or magnesium: may affect absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): may require dose adjustment. - Warfarin: potential for altered anticoagulant effect, monitor INR. - Statins metabolized by CYP3A4 (e.g., simvastatin): monitor for myopathy.